Stamford, CT -- (SBWIRE) -- 08/16/2013 -- High Rising Stocks provides investors with the hot penny stock alerts on a regular basis. We will send you alerts through our Free E Newsletters with High Yielding alerts, market forecasting, stock tips and strategies, and offer you the tools to help you along the way with the goal of keeping you loyal to our service. Today’s stocks to watch are: Sunedison Inc. (NYSE:SUNE), Hercules Offshore, Inc. (NASDAQ:HERO), Halcon Resources Corp (NYSE:HK), Keryx Biopharmaceuticals (NASDAQ:KERX)
Sunedison Inc. (NYSE:SUNE) augmented 2.47% to $7.06 on a traded volume of 722k shares. Ardour Capital lowered the rating on the stock from buy to hold. SunEdison Inc. is engaged in the development, manufacture and sale of silicon wafers. The Company is a developer and seller of photovoltaic energy solutions.
Is SUNE A Strong At The CMP? Get Advantage Of Our Free Trend Analysis Here
Hercules Offshore, Inc. (NASDAQ:HERO) went up 0.94% to $6.99 on a traded volume of 493k shares. So far this year, the stock is up over 18%. The 52-week range for the stock is $3.95 and $7.96. Hercules Offshore, Inc. provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry globally.
Is HERO A Good Buy After The Recent Price Movement? Find Out Here
Halcon Resources Corp (NYSE:HK) declined 0.58% to $5.18 on a traded volume of 1.20 million shares. Canaccord Genuity lowered the price target on shares of Halcon Resources Corp from $7.50 to $7.00 in a report issued. The firm currently has a “buy” rating on the stock. Halcon Resources Corporation is an independent energy company focused on the acquisition, production, exploration and development of onshore liquids-rich oil and natural gas assets in the United States.
Should Investors Rush To Buy HK After The Solid Rally? Get Special Report Here
Keryx Biopharmaceuticals (NASDAQ:KERX) slipped 1.28% to $8.47 on a traded volume of 520k shares. Keryx Biopharmaceuticals announced the submission of a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Zerenex™, the Company's drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease on dialysis.
How Should Investors Trade KERX After The Recent Volatility? Get Free Report Here
High Rising Stocksis always searching the market every day for massive penny stock runs before they happen so you don't have to.We will send you alerts through our Free E Newsletters with High Yielding alerts, market forecasting, stock tips and strategies, and offer you the tools to help you along the way with the goal of keeping you loyal to our service.
Carriage Consulting Group, High Rising Stocks, their Members, officers, directors, employees, affiliates, or any other related person(s) (collectively, “High Rising Stocks”) are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. High Rising Stocks as defined are neither licensed nor qualified to provide investment advice and you are specifically and adamantly advised not to rely upon anything said/posted/communicated/implied or expressed by High Rising Stocks as defined.
Read full Disclaimer at: http://highrisingstocks.com/disclaimer/
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)